Core Viewpoint - The FDA's decision to eliminate a key advisory committee meeting for Travere Therapeutics' drug Filspari is seen as a positive indicator for its approval in treating focal segmental glomerulosclerosis (FSGS), a kidney disease with high unmet medical needs [1][4]. Company Summary - Travere Therapeutics' stock surged 18% to $25.52 following the FDA's announcement, positioning it for a nearly three-year high in premarket trading [4]. - The company’s stock has a strong IBD Digital Composite Rating of 96, indicating it outperforms 96% of all stocks based on fundamental and technical measures [5]. Industry Summary - Filspari is already approved for treating IgA nephropathy (IgAN) and would be the first drug approved for FSGS based on evidence of reducing proteinuria [2][3]. - The advisory committee typically assesses the benefits and risks of drugs before recommending FDA approval, but the cancellation of this meeting suggests confidence in the drug's efficacy and safety [3][4].